Compounds > alanine
Page last updated: 2024-11-08

alanine and Headache

alanine has been researched along with Headache in 3 studies

Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.

Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.

Research Excerpts

ExcerptRelevanceReference
"To characterize clinical features of a very large pedigree with early-onset Alzheimer disease (AD) in which all affected individuals carry the identical glutamic acid-to-alanine mutation at codon 280 in the presenilin-1 gene."3.69Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. ( Arango-Lasprilla, JC; Arango-Viana, JC; Arcos-Burgos, M; Ardilla, A; Behrens, IM; Goate, AM; Hincapíe, L; Kosik, KS; Lemere, CA; Lendon, C; Lopera, F; Madrigal, L; Martínez, A; Norton, J; Ossa, JE; Rosselli, M; Ruiz-Linares, A, 1997)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19901 (33.33)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sax, PE1
Wohl, D1
Yin, MT1
Post, F1
DeJesus, E1
Saag, M1
Pozniak, A1
Thompson, M1
Podzamczer, D1
Molina, JM1
Oka, S1
Koenig, E1
Trottier, B1
Andrade-Villanueva, J1
Crofoot, G1
Custodio, JM1
Plummer, A1
Zhong, L1
Cao, H1
Martin, H1
Callebaut, C1
Cheng, AK1
Fordyce, MW1
McCallister, S1
Lopera, F1
Ardilla, A1
Martínez, A1
Madrigal, L1
Arango-Viana, JC1
Lemere, CA1
Arango-Lasprilla, JC1
Hincapíe, L1
Arcos-Burgos, M1
Ossa, JE1
Behrens, IM1
Norton, J1
Lendon, C1
Goate, AM1
Ruiz-Linares, A1
Rosselli, M1
Kosik, KS1
Stanley, RJ1
Melson, GL1
Cubillo, E1
Hesker, AE1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Trea[NCT01780506]Phase 3872 participants (Actual)Interventional2012-12-26Completed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treat[NCT01797445]Phase 3872 participants (Actual)Interventional2013-03-12Completed
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994]275 participants (Actual)Observational [Patient Registry]2018-02-06Active, not recruiting
Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE) - A Phase II Exploratory Study[NCT04004702]Phase 265 participants (Anticipated)Interventional2020-01-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in CD4+ Cell Count at Week 144

(NCT01780506)
Timeframe: Baseline; Week 144

Interventioncells/µL (Mean)
E/C/F/TAF323
E/C/F/TDF310

Change From Baseline in CD4+ Cell Count at Week 48

(NCT01780506)
Timeframe: Baseline; Week 48

Interventioncells/µL (Mean)
E/C/F/TAF235
E/C/F/TDF221

Change From Baseline in CD4+ Cell Count at Week 96

(NCT01780506)
Timeframe: Baseline; Week 96

Interventioncells/µL (Mean)
E/C/F/TAF285
E/C/F/TDF271

Change From Baseline in Serum Creatinine at Week 144

(NCT01780506)
Timeframe: Baseline; Week 144

Interventionmg/dL (Mean)
E/C/F/TAF0.04
E/C/F/TDF0.08

Change From Baseline in Serum Creatinine at Week 48

(NCT01780506)
Timeframe: Baseline; Week 48

Interventionmg/dL (Mean)
E/C/F/TAF0.08
E/C/F/TDF0.11

Change From Baseline in Serum Creatinine at Week 96

(NCT01780506)
Timeframe: Baseline; Week 96

Interventionmg/dL (Mean)
E/C/F/TAF0.05
E/C/F/TDF0.07

Percent Change From Baseline in Hip BMD at Week 144

Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144

Interventionpercent change (Mean)
E/C/F/TAF-0.826
E/C/F/TDF-3.475

Percent Change From Baseline in Hip BMD at Week 96

Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96

Interventionpercent change (Mean)
E/C/F/TAF-0.951
E/C/F/TDF-3.515

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01780506)
Timeframe: Baseline; Week 48

Interventionpercent change (Mean)
E/C/F/TAF-0.865
E/C/F/TDF-3.200

Percent Change From Baseline in Spine BMD at Week 144

Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144

Interventionpercent change (Mean)
E/C/F/TAF-0.809
E/C/F/TDF-3.023

Percent Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 48

Interventionpercent change (Mean)
E/C/F/TAF-1.337
E/C/F/TDF-2.956

Percent Change From Baseline in Spine BMD at Week 96

Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96

Interventionpercent change (Mean)
E/C/F/TAF-0.907
E/C/F/TDF-3.053

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 144

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144

Interventionpercent change (Median)
E/C/F/TAF-24.6
E/C/F/TDF60.4

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48

Interventionpercent change (Median)
E/C/F/TAF-32.8
E/C/F/TDF18.0

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96

Interventionpercent change (Median)
E/C/F/TAF-33.5
E/C/F/TDF32.5

Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 144

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144

Interventionpercent change (Median)
E/C/F/TAF37.4
E/C/F/TDF106.9

Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96

Interventionpercent change (Median)
E/C/F/TAF11.3
E/C/F/TDF75.0

Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48

Interventionpercent change (Median)
E/C/F/TAF6.9
E/C/F/TDF51.2

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Week 48

Interventionpercentage of participants (Number)
E/C/F/TAF93.1
E/C/F/TDF92.8

Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 144

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 144 weeks

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3
E/C/F/TAF31.36.00.2
E/C/F/TDF37.17.00.2

Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 48

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 48 weeks

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3
E/C/F/TAF25.84.60
E/C/F/TDF32.34.90.2

Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 96

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 96 weeks

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3
E/C/F/TAF28.85.10.2
E/C/F/TDF33.95.80.2

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48, 96, and 144

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48, 96, and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 48, 96. and 144

,
Interventionpercentage of participants (Number)
Week 48Week 96Week 144
E/C/F/TAF86.484.484.6
E/C/F/TDF87.383.680.1

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 and 144

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Weeks 96 and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 96 and 144

,
Interventionpercentage of participants (Number)
Week 96Week 144
E/C/F/TAF89.286.9
E/C/F/TDF88.283.1

Change From Baseline in CD4+ Cell Count at Week 48

(NCT01797445)
Timeframe: Baseline; Week 48

Interventioncells/µL (Mean)
E/C/F/TAF225
E/C/F/TDF200

Change From Baseline in CD4+ Cell Count at Week 96

(NCT01797445)
Timeframe: Baseline; Week 96

Interventioncells/µL (Mean)
E/C/F/TAF274
E/C/F/TDF260

Change From Baseline in Serum Creatinine at Week 48

(NCT01797445)
Timeframe: Baseline; Week 48

Interventionmg/dL (Mean)
E/C/F/TAF0.08
E/C/F/TDF0.12

Change From Baseline in Serum Creatinine at Week 96

(NCT01797445)
Timeframe: Baseline; Week 96

Interventionmg/dL (Mean)
E/C/F/TAF0.04
E/C/F/TDF0.07

Percent Change From Baseline in Hip BMD at Week 96

Hip BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96

Interventionpercent change (Mean)
E/C/F/TAF-0.364
E/C/F/TDF-3.023

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01797445)
Timeframe: Baseline; Week 48

Interventionpercent change (Mean)
E/C/F/TAF-0.420
E/C/F/TDF-2.603

Percent Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 48

Interventionpercent change (Mean)
E/C/F/TAF-1.278
E/C/F/TDF-2.759

Percent Change From Baseline in Spine BMD at Week 96

Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96

Interventionpercent change (Mean)
E/C/F/TAF-1.017
E/C/F/TDF-2.516

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48

Interventionpercent change (Median)
E/C/F/TAF-29.3
E/C/F/TDF32.3

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96

Interventionpercent change (Median)
E/C/F/TAF-31.0
E/C/F/TDF35.2

Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96

Interventionpercent change (Median)
E/C/F/TAF16.9
E/C/F/TDF73.7

Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48

Interventionpercent change (Median)
E/C/F/TAF13.3
E/C/F/TDF51.7

Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Week 48

Interventionpercentage of participants (Number)
E/C/F/TAF91.6
E/C/F/TDF88.5

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Week 96

Interventionpercentage of participants (Number)
E/C/F/TAF84.0
E/C/F/TDF82.3

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48 and 96

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48 and 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Weeks 48 and 96

,
Interventionpercentage of participants (Number)
Week 48Week 96
E/C/F/TAF82.478.7
E/C/F/TDF80.776.8

Percentage of Participants With Treatment-emergent Proteinuria Through Week 48

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01797445)
Timeframe: Baseline to Week 48

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3
E/C/F/TAF27.34.70
E/C/F/TDF31.64.60

Percentage of Participants With Treatment-emergent Proteinuria Through Week 96

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01797445)
Timeframe: Baseline to Week 96

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3
E/C/F/TAF31.85.40
E/C/F/TDF36.95.10

Trials

2 trials available for alanine and Headache

ArticleYear
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987

    Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count

2015
A comparison of three cholecystographic agents. A double-blind study with and without a prior fatty meal.
    Radiology, 1974, Volume: 112, Issue:3

    Topics: Alanine; Butyrates; Cholecystography; Clinical Trials as Topic; Contrast Media; Diarrhea; Dietary Fa

1974

Other Studies

1 other study available for alanine and Headache

ArticleYear
Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation.
    JAMA, 1997, Mar-12, Volume: 277, Issue:10

    Topics: Adult; Age of Onset; Alanine; Alzheimer Disease; Autopsy; Brain; Codon; Female; Glutamic Acid; Heada

1997
chemdatabank.com